Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | TYK2 | P29597 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | PREP | P48147 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128832 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL5368396 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL16903351 | 0.96 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| Formic Acid SCHEMBL28339396 | 0.95 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL18084804 | 0.95 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL1841984 | 0.92 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL492951 | 0.92 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL18084813 | 0.92 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL540519 | 0.92 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL13547248 | 0.89 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791425-A | Synthesis method of 1-BOC-3-piperidone and similar cyclic ketone compounds thereof | 浙江尚科生物医药有限公司 | 2024-10-18 | — | — | CN | claimed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4626865-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4587446-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118791425-A | Synthesis method of 1-BOC-3-piperidone and similar cyclic ketone compounds thereof | 浙江尚科生物医药有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4408850-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-115003671-B | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
| EP-0487411-B1 | Erythromycin derivatives, their preparation, intermediates obtained and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-01-31 | — | — | EP | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| US-5444051-A | BACTERICIDES | ROUSSEL UCLAF (FR) | 1995-08-22 | — | — | US | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
| US-5407943-A | Azaspiro quinolone antibacterial agents | PFIZER INC. (US) | 1995-04-18 | — | — | US | disclosed |
| EP-0641339-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| WO-1992022550-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1992-12-23 | — | — | WO | disclosed |
| EP-0487411-A1 | Erythromycin derivatives, their preparation, intermediates obtained and their application as medicaments | ROUSSEL UCLAF (FR) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | SMN1; SMN2 3375/4885NPC1 1363/4885RAB9A 1690/4885 |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, TRPM2, PKD2 | SMN1; SMN2 1638/4885NPC1 43/4885RAB9A 1163/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | SMN1; SMN2 4444/4885NPC1 2647/4885RAB9A 55/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | SMN1; SMN2 4096/4885NPC1 1305/4885RAB9A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.